Patient and Kidney Allograft Survival in Recipients with End-Stage Renal Disease from Amyloidosis

Transplantation

Volumn 102, Issue 2, 2018, Pages 300-309

  Sawinski, Deirdre ^a   Lim, Mary Ann ^a   Cohen, Jordana B ^a   Locke, Jayme E ^b   Weiss, Brendan ^c,d   Hogan, Jonathan J ^a,c   Dember, Laura M ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYLOIDOSIS; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE; ALLOTRANSPLANTATION; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROPENSITY SCORE;

ADULT; AMYLOIDOSIS; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 85041578968     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001930     Document Type: Article

References (39)

1. Sipe JD Benson MD Buxbaum JN. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014; 21: 221-224.
2. Nienhuis HL Bijzet J Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis (Basel). 2016; 2: 10-19.
3. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006; 1: 1331-1341.
4. Westermark P Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci. 2008; 363: 3701-3705.
5. Said SM Valeri AM Leung N. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013; 8: 1515-1523.
6. Dember LM. Amyloidosis-Associated kidney disease. J Am Soc Nephrol. 2006; 17: 3458-3471.
7. Gertz MA Kyle RA O'Fallon WM. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med. 1992; 152: 2245-2250.
8. Kyle RA Greipp PR O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986; 68: 220-224.
9. Palladini G Hegenbart U Milani P. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124: 2325-2332.
10. Nuvolone M Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017; 32: 770-780.
11. Casserly LF Fadia A Sanchorawala V. High dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-Associated end-stage renal disease. Kidney Int. 2003; 63: 1051-1057.
12. Muchtar E Gertz MA Kumar SK. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017; 129: 2111-2119.
13. Lachmann HJ Gallimore R Gillmore JD. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003; 122: 78-84.
14. Wechelaker AD Gillmore JD Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387: 2641-2654.
15. D'Souza A Dispenzieri A Wirk B. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J CLin Oncol. 2015; 33: 3741-3749.
16. Lachmann HJ Goodman HJ Gilbertson JA. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356: 2361-2371.
17. Gillmore JD Lovat LB Persey MR. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358: 24-29.
18. Pasternack A Ahonen J Kuhlbäck B. Renal transplantation in 45 patients with amyloidosis. Transplantation. 1986; 42: 598-601.
19. Bleyer AJ Donaldson LA McIntosh M. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis. 2001; 37: 1152-1161.
20. Sherif AM Rafeie AF Sobh MA. Long-Term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis. 2003; 42: 370-375.
21. Sattianayagam PT Gibbs SD Pinney JH. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010; 10: 2124-2131.
22. Pinney JH Lachmann HJ Sattianayagam PT. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant. 2013; 13: 433-441.
23. Herrmann SM Gertz MA Stegall MD. Long-Term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011; 26: 2032-2036.
24. Kofman T Grimbert P Canouï-Poitrine F. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant. 2011; 11: 2423-2431.
25. Weitzen S Lapane KL Toledano AY. Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf. 2004; 13: 841-853.
26. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006; 9: 377-385.
27. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28: 3083-3107.
28. Rubin DB. Using propensity scores to help design observational studies: Application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001; 2: 169-188.
29. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013; 32: 2837-2849.
30. Yin DY Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989; 84: 1074-1078.
31. Therneau TM Grambsch PM. Modeling survival data: extending the cox model. New York, NY: Springer; 2001.
32. Cox D. Regression models and life tables. J R Stat Soc Ser. 1972; 34: 187-220.
33. Rothman KJ Greenland S. Modern epidemiology. 2nd ed. Philadelphia, USA: Lippincott Williams and Wilkins; 1998.
34. White IR Carline JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med. 2010; 29: 2920-2931.
35. Bartlett JW Carpenter JR Tilling K. Improving upon the efficiency of complete case analysis when covariates are MNAR. Biostatistics. 2014; 15: 719-730.
36. Rao PS Schaubel DE Guidinger MK. A comprehensive risk quantification score for deceased donor kidneys: The kidney donor risk index. Transplantation. 2009; 88: 231-236.
37. Cohen JB Bloom RD Reese PP. National outcomes of kidney transplantation from deceased diabetic donors. Kidney Int. 2016; 89: 636-647.
38. Faravardeh A Eickhoff M Jackson S. Predictors of graft failure and death in elderly kidney transplant recipients. Transplantation. 2013; 96: 1089-1096.
39. Narayanan M Pankewycz O Shihab F. Long-Term outcomes in African American kidney transplant recipients under contemporary immunosuppression: A four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study. Clin Transplant. 2014; 28: 184-191.